Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

96 Background: Prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) targeted to prostate-specific membrane antigen (PSMA) is a new targeted treatment for progressive metastatic castration-resistant prostate cancer (mCRPC). PSMA-RLT conjugates a radionuclide to a small molecule ligand with affinity for PSMA. Recent trials, such as TheraP and VISION, established improvements in...

  • 123456 Profile photo of Madelyn

    Pain improved with Lu-PSMA among patients with symptomatic bone mets at start of therapy.